Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk says diabetes drug candidate successful in phase III trials

Danish pharmaceutical company Novo Nordisk has revealed that its diabetes drug candidate liraglutide has shown positive results in two phase III clinical trials.

Danish pharmaceutical company Novo Nordisk has revealed that its diabetes drug candidate liraglutide has shown positive results in two phase III clinical trials.

The trials, which are the second and third in a series of five phase three studies in the group's ongoing LEAD programme, showed that the compound improved glucose control and lowered the body weight of the participants.

Liraglutide is a long-acting analogue of the naturally occurring hormone, Glucagon-Like Peptide-1 (GLP-1), which is rapidly broken down in the body and thus not practical as a therapy for type 2 diabetes. Studies to date show that liraglutide significantly improves glycaemic control in monotherapy and in combination therapy with metformin.

The trial results do not affect Novo Nordisk's previous financial expectations for 2007.

Novo Nordisk said it would post results from the remaining two LEAD studies in H2 2007 and Q1 2008.

Novo Nordisk's CSO, Mads Krogsgaard Thomsen, said of the data: "The encouraging clinical results from the two new trials confirm the positive effect of Liraglutide and leave us confident that we are on track to submit for regulatory approval mid-2008."

20th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics